FIGURE 3.

Pseudoatrophy analysis, 0–6 months, from 267 patients treated with cladribine 3.5 mg/kg and 265 patients treated with placebo. Pseudoatrophy was present both in grey matter (GM) and white matter (WM) during the first 6 months of therapy, with a significant difference in percentage volume change between cladribine and placebo for GM only. The ∆% change in the treated group and the standard errors are indicated in the figure. Abbreviations: CladT3.5, cladribine tablets 3.5 mg/kg; PVC, percentage volume change